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Introduction 
With the growing interest in the clinical sequelae associ-
ated with homocysteinemia, attention has been directed to-
wards studies of the enzymes responsible for the generation 
and consumption of homocysteine. As shown in Figure 1, 
methylenetetrahydrofolate reductase and methionine synthase 
are two such enzymes. Methylenetetrahydrofolate reductase 
catalyzes the reduction of methylenetetrahydrofolate to me-
thyltetrahydrofolate. This is the only reaction generating me-
thyltetrahydrofolate in the cell. Methionine synthase catalyzes 
a methyl transfer from methyltetrahydrofolate to homocyste-
ine, generating methionine and tetrahydrofolate. In bacteria, 
the reaction catalyzed by methionine synthase is the termi-
nal reaction in the de novo biosynthesis of methionine; in hu-
mans, for whom methionine is an essential amino acid, this 
reaction serves to regenerate the methyl group of methionine. 
As indicated in Figure 1, methionine is converted to adeno-
sylmethionine (AdoMet), which serves as a methyl donor in 
numerous biosynthetic reactions. The product adenosylhomo-
cysteine (AdoHcy) is then hydrolyzed to form adenosine and 
homocysteine. Homocysteine can be reconverted to methio-
nine to provide another methyl group. 
Homocysteine is a metabolite at a critical branch point 
in 1-carbon metabolism. If the cell is replete with AdoMet, 
and the ratio of AdoMet/AdoHcy is high, methylenetetrahy-
drofolate reductase is inhibited. Under these conditions the 
level of methyltetrahydrofolate in the cell is low, and ho-
mocysteine is degraded by conversion to cystathionine and 
thence to α-ketobutyrate, ammonia, and cysteine. If the ratio 
of AdoMet/AdoHcy is low, signalling a need for synthesis of 
more AdoMet, methylenetetrahydrofolate reductase inhibition 
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Abstract 
Methylenetetrahydrofolate reductase and cobalamin-dependent methionine synthase catalyze the penultimate and ultimate 
steps in the biosynthesis of methionine in prokaryotes, and are required for the regeneration of the methyl group of methi-
onine in mammals. Defects in either of these enzymes can lead to hyperhomocysteinemia. The sequences of the human 
methylenetetrahydrofolate reductase and methionine synthase are now known, and show clear homology with their bacte-
rial analogues. Mutations in both enzymes that are known to occur in humans and to be associated with hyperhomocystein-
emia affect residues that are conserved in the bacterial enzymes. Structure/function studies on the bacterial proteins, sum-
marized in this review, are therefore relevant to the function of the human enzymes; in particular studies on the effects of 
bacterial mutations analogous to those causing hyperhomocysteinemia in human may shed light on the defects associated 
with these mutations. 
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is relieved, and methyltetrahydrofolate is produced to support 
the reaction of methionine synthase. Studies by Kutzbach and 
Stokstad [24] demonstrated that methylenetetrahydrofolate 
reductase acitvity is allosterically regulated by the AdoMet/
AdoHcy ratio, with AdoMet serving as an inhibitor, and Ado-
Hcy competing with AdoMet for binding to the reductase but 
not acting as an inhibitor. 
Defects in either methylenetetrahydrofolate reductase [21, 
22, 31] or methionine synthase [35, 41] can lead to hyperhomo-
cysteinemia, as can deficiencies in β-cystathionase activity [2]. 
Severe defects, which lead to greatly elevated blood homocys-
teine levels, were the first to be identified, but recently we have 
realized that defects that lead to mild elevations in blood homo-
cysteine levels are potential long-term risk factors [13, 37, 43]. 
Such mild defects may be associated with polymorphisms. 
During the past 3 years, the nucleotide sequences for the 
human cDNAs specifying methylenetetrahydrofolate reduc-
tase [16] and methionine synthase [3, 25, 26] have been pub-
lished. The availability of these sequences permits the iden-
tification of mutations that lead to impaired function of these 
enzymes, and hence to homocysteinemia. We are thus in-
creasingly able to identify humans at risk for homocystein-
emia and its sequelae. Extensive structural and functional 
studies of either the mammalian enzymes or their prokaryotic 
analogues have been performed, and thus studies can assist in 
understanding the defects associated with specific mutations, 
and can suggest strategies to ameliorate the symptoms caused 
by these mutations. 
Methylenetetrahydrofolate reductase 
Most of our knowledge about the structure and function 
of human methylenetetrahydrofolate reductase derives from 
studies of the closely related porcine enzyme. This enzyme 
was initially characterized by Kutzbach and Stokstad, and has 
subsequently been extensively studied in our laboratory. Kutz-
bach and Stokstad [24] partially purified the enzyme from 
porcine liver, and showed that it was allosterically regulated 
by AdoMet. The enzyme was subsequently purified to homo-
geneity [5], and shown to contain one equivalent of non-cova-
lently bound FAD per enzyme subunit. The enzyme is a dimer 
of identical 77 kDa subunits. Tryptic proteolysis of the native 
enzyme was shown to cleave each subunit into two fragments, 
an N-terminal 40 kDa fragment and a C-terminal 37 kDa frag-
ment [30]. Tryptic cleavage results in loss of allosteric reg-
ulation of enzyme activity by AdoMet, but has no effect on 
the catalytic activity of the enzyme, suggesting that the pro-
tein may consist of separate catalytic and regulatory regions 
[30]. AdoMet was subsequently shown to bind to the Ctermi-
nal 37 kDa fragment, implicating this fragment as the regula-
tory region [38]. 
The deduced amino acid sequence of the human enzyme 
provided further insight into the functional organization of 
methylenetetrahydrofolate reductase. The N-terminal region 
of the human protein showed extensive similarity with smaller 
proteins from enteric bacteria that catalyze the same reaction, 
namely the NAD(P)H-dependent reduction of methylenetetra-
hydrofolate. Since the activity of these enzymes is not allo-
sterically regulated by AdoMet, there was a strong inference 
that the N-terminal region of the human enzyme is the cata-
lytic region, and contains determinants for binding of FAD, 
NADPH, and methylenetetrahydrofolate. The C-terminal re-
gion of the human enzyme shows sequence similarities with 
the enzymes from yeast and from the roundworm Caenorhab-
ditis elegans but this region is lacking in the bacterial methy-
lenetetrahydrofolate reductases. The human enzyme contains 
an extremely hydrophilic region, Lys-Arg-Arg-Glu- Glu-Asp, 
that bridges the catalytic and regulatory regions; cleavage be-
tween Lys and Arg residues in this region would divide the 
protein into 40 and 34 kDa fragments. The sequence of a pep-
tide in the porcine enzyme that is labeled by irradiation of 
methylenetetrahydrofolate reductase in the presence of [3H-
methyl] AdoMet has been determined; a sequence similar to 
this peptide is located immediately downstream of the tryptic 
cleavage site [16]. 
Methylenetetrahydrofolate reductase from Escherichia 
coli had only previously been characterized in relatively im-
pure preparations [23], and we have developed a method to 
purify this enzyme to homogeneity from an overexpress-
ing strain. The purified enzyme is a flavoprotein, and con-
tains non-covalently bound FAD as its cofactor. The enzyme-
bound flavin is reduced by NADH, and much more slowly by 
NADPH, and can in turn reduce methylenetetrahydrofolate to 
methyltetrahydrofolate. 
Rozen and her collaborators [13, 16, 17] have conducted 
an extensive search for mutations in the human methylene-
tetrahydrofolate reductase gene, concentrating especially on 
mutations in the N-terminal catalytic region. Several muta-
tions associated with severe deficiency in patients have been 
Figure 1. Pathways involved in the production of methyltetrahydro-
folate and in the regeneration of homocysteine to form methionine. 
Enzymes (1) are the methionine adenosyltransferase isozymes, en-
zymes (2) are AdoMet-dependent methyltransferases, and enzyme 
(3) is S-adenosylhomocysteine hydrolase. CH2-H4folate methylene-
tetrahydrofolate, CH3-H4folate methyltetrahydrofolate, H4folate tet-
rahydrofolate, AdoHcy adenosylhomocysteine, Pi phosphate anion, 
P-Pi pyrophosphate anion.  
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identified, two such point mutations are Arg157Gln, and 
Thr227Met. A polymorphism, Ala222Val, has been shown to 
be present in high frequency in humans; in a population of 
French Canadians Ala/Val heterozygotes are present at 51% 
frequency, and Val/Val homozymgotes at 12% frequency [13]. 
Humans who are homozygous for the polymorphism have re-
duced specific activity of methylenetetrahydrofolate reduc-
tase in fibroblast extracts, and demonstrate increased suscep-
tibility to heat inactivation of enzyme activity (as assessed by 
measuring reductase activity after heating for 5 min at 46°C 
and comparing with the activity of controls) [13]. The Val/
Val genotype has subsequently been shown to be associated 
with increased risk for neural tube defects [40, 42], and possi-
bly for the develoment of cardiovascular disease [11, 28], al-
though not all studies have found significant correlations [6]. 
Each of the mutated residues, Arg157, Thr227, and Ala222, is 
conserved in the bacterial, yeast, and roundworm sequences 
of methylenetetrahydrofolate reductase. 
Because the human methylenetetrahydrofolate reductase 
has not yet successfully been overexpressed and purified, we 
have constructed a homologous mutation to Ala222Val in the 
methylenetetrahydrofolate reductase from E. coli, Ala177Val. 
This mutation leads to diminished expression of methylene-
tetrahydrofolate reductase in an overexpressing strain, and the 
enzyme activity is rapidly lost during purification. We have 
successfully purified the mutant bacterial enzyme to homoge-
neity by introducing a histidine tag at the C-terminus of the 
protein and purifying the enzyme on nickel Sepharose. Our 
present studies suggest that the Ala177Val bacterial enzyme is 
indeed thermolabile, and that it readily loses its flavin cofactor 
on dilution of the protein. 
The reduced specific activity of methylenetetrahydrofolate 
reductase in humans with the thermolabile mutation [11], and 
the resultant elevation in homocysteine in patients with low 
folate status [19], may similarly reflect the presence of inac-
tive apo-enzyme in the cells of these individuals. 
Methionine synthase 
Cobalamin-dependent methionine synthase from E. coli was 
initially characterized in the laboratories of Wood, Weissbach, 
and Huennekens (reviewed in [29]). These studies established 
the participation of the cobalamin (B12) cofactor in the methyl 
transfer from methyltetrahydrofolate to homocysteine, and de-
fined the requirements for catalytic turnover. As shown in Fig-
ure 2, the cofactor cycles in catalysis between the methylcobal-
amin form and the cob(I)alamin form. Cob(I)alamin is a strong 
reductant, and is occasionally oxidized during catalytic turn-
over in the presence of oxygen to produce the inactive cob(II)
alamin form of the enzyme. Return of this form of the enzyme 
to the catalytic cycle requires a reductive methylation, in which 
the methyl group is provided by AdoMet [27]; in E. coli, re-
duced flavodoxin serves as the electron donor [14]. Thus cat-
alytic turnover in the presence of oxygen requires homocyste-
ine and methyltetrahydrofolate, AdoMet and a reducing system. 
The E. coli methionine synthase was first cloned, overex-
pressed and sequenced in 1989–1990 [1, 32, 33]. As noted 
above, the sequence of the human methionine synthase has 
been simultaneously determined in three laboratories this year 
[3, 25, 26]. The human enzyme shows 58% identity with me-
thionine synthase from E. coli [3]. These two sequences, as 
well as sequences from the roundworm Caenorhabditis ele-
gans [39], and the prokaryotes Hemophilus influenzae [12], 
Mycobacterium leprae [36], and Synechocystis sp. strain 
PCC6803 [20], are aligned in Figure 3. Given the high de-
gree of conservation of amino acid residues throughout the 
proteins, the enzymes from these organisms are likely to have 
very similar properties and structures. Thus the large body of 
information available for the E. coli enzyme is likely to be rel-
evant to the human enzyme. 
The porcine methionine synthase has been purified to ho-
mogeneity [4] and shown to be similar in size and proper-
ties to the enzyme from E. coli. The one respect in which the 
mammalian enzymes clearly differ from the bacterial proteins 
is in the nature of the biological reducing system. Mammals 
lack flavodoxin, necessary for reductive reactivation in E. 
coli; the proteins responsible for reductive activation in mam-
mals have not yet been identified. 
Our recent studies on the bacterial enzyme have shown it 
to be a modular protein, consisting of four regions that are 
designated in Figure 3. The N-terminal module (residues 
1–353 in the E. coli sequence) is responsible for binding and 
Figure 2. Chemistry of the methionine synthase (MS) reaction. In 
normal catalysis the B12 prosthetic group cycles a between cob(I)ala-
min (CO(I)) and methylcobalamin (Co-CH3). Homocysteine demeth-
ylates methylcobalamin to generate methionine and cob(I)alamin and 
the latter is remethylated by methyltetrahydrofolate (CH3-H4folate) 
with formation of tetrahydrofolate. Occasionally, the cob(I)alamin 
form of the enzyme becomes oxidized to the inactive cob(II)alamin 
form of the enzyme. Return of this form of the enzyme to the cata-
lytic cycle requires a reductive methylation. In E. coli, the electron is 
supplied by reduced flavodoxin; the electron donor in mammals has 
not yet been identified. AdoMet supplies the methyl group for reduc-
tive activation.  
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activation of homocysteine (Goulding and Matthews, unpub-
lished data) and shows sequence similarity with human beta-
ine-homocysteine methyltransferase [15]. The next module, 
comprising residues 354–649, is involved in the binding and 
activation of methyltetrahydrofolate. This module shows se-
quence similarities with a methyltransferase from Clostrid-
ium thermoaceticum that catalyzes methyl transfer from me-
thyltetrahydrofolate to a separate corrinoid iron/sulfur protein 
[34]. The third module of the bacterial enzyme, comprising 
residues 650–896, contains the determinants for binding the 
cobalamin cofactor [1, 8, 34], and presents the cofactor to the 
other three modules. A high resolution X-ray structure of this 
module has been determined [8]. The fourth and last module, 
containing residues 897–1227, binds AdoMet and is required 
for reductive activation of methionine synthase [9]. An X-ray 
structure of this module, with AdoMet bound, has recently 
been determined [7]. 
Thus, as mutations and polymorphisms of human methio-
nine synthase are identified, we may be able to guess at their 
probable phenotypes from their location in the sequence. One 
such mutation, Pro1137Leu, is associated with severe disease 
in humans [18]. This mutation is located in the activation mod-
ule of methionine synthase, adjacent the bound AdoMet. This 
mutation has a very interesting phenotype; it is active when as-
sayed using a chemical reducing system, but shows very low 
activity when assayed with the biological reducing system 
[18]. Thus this mutation in the activation domain of methio-
nine synthase appears to have altered the interaction of human 
methionine synthase with its biological reducing agent. 
Figure 3. Aligment of the methionine synthase sequence from Homo 
sapiens [3, 25, 26] with the sequence from the E. coli metH gene 
[1, 10, 33], and homologous sequences from the roundworm Cae-
norhabditis elegans [39], and the prokaryotes Hemophilus influen-
zae [12]. Mycobacterium leprae [36], and Synechocystis sp. strain 
PCC6803 [20]. Identical residues are shown in bold. The Hemoph-
ilus sequence appears to lack most of the N-terminal portion of the 
sequence of the other genes, perhaps because it was obtained by 
shotgun cloning of the entire genome.
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Analysis of other mutations and polymorphisms may not 
only tell us whether methionine synthase mutations are inde-
pendent risk factors for neural-tube defects and/or cardiovas-
cular disease, but may also tell us much about the role of the 
methionine synthase protein in catalyzing methyl transfer. 
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